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Abstract
Introduction Treatment with sirolimus, a mammalian target of
rapamycin (mTOR) inhibitor, has been shown to be efficacious
in the MRL/lpr and NZB × NZW F1 mouse models of lupus
nephritis, indicating a critical role for the mTOR pathway in both
models. This type of demonstration of efficacy in animal models
is usually a pre-requisite for advancement into clinical
development. However, efficacy in an animal model often has
not translated to the desired activity in the clinic. Therefore, a
more profound understanding of the mechanistic similarities and
differences between various animal models and human
diseases is highly desirable.
Methods Transcriptional profiling was performed on kidneys
from mice with lupus nephritis; from mice who had efficacious
drug treatment; and from mice before they developed nephritis.
Analysis of variance with false discovery rate adjusted to p <
0.05 and an average fold change of two or more was used to
identify transcripts significantly associated with disease and
response to therapy. Pathway analyses (using various
bioinformatics tools) were carried out to understand the basis
for drug efficacy in the mouse model. The relevance in human
lupus of the pathways identified in the mouse model was
explored using information from several databases derived from
the published literature.
Results We identified a set of nephritis-associated genes in
mouse kidney. Expression of the majority of these returned to
asymptomatic levels on sirolimus treatment, confirming the
correlation between expression levels and symptoms of
nephritis. Network analysis showed that many of these nephritis
genes are known to interact with the mTOR pathway. This led us
to ask what human diseases are linked to the mTOR pathway.
We constructed the mTOR pathway interactome consisting of
proteins that interact with members of the mTOR pathway and
identified a strong association between mTOR pathway genes
and genes reported in the literature as being involved in human
lupus.
Conclusions Our findings implicate the mTOR pathway as a
critical contributor to human lupus. This broad pathway-based
approach to understanding the similarities in, and differences
between, animal models and human diseases may have broader
utility.
Introduction
Clinical development of therapies is heavily dependent on
demonstrated efficacy in animal model(s), but efficacy in ani-
mal models often does not translate into clinical success. A
number of factors have been proposed as contributing to this
lack of concordance between efficacy in animal and clinical
studies [1-5]. One clear limitation of relying on disease models
in inbred strains is that the genes that produce the disease
phenotype in a given model may represent only a subset of the
genes that can cause the phenotype in complex human
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diseases such as lupus. Using our own animal model tran-
scriptomics, the vast and rapidly accumulating literature on
genes linked to human disease and pathway tools, we have
taken a broad analytical approach to identifying similarities
between the mouse and human 'lupus phenotype' at the level
of biological pathway perturbations. The potential advantage
of this approach is that, by linking the human disease pheno-
type to a pathway, drug development efforts can be targeted
to the pathway. Animal models with involvement of the same
pathway can then be chosen and/or derived.
Systemic lupus erythematosus (SLE) is a chronic inflammatory
autoimmune disease [6-8]. The pathophysiology of disease is
manifested by the production of autoantibodies directed
against multiple self-antigens. This dysregulation of the
immune system resulting in the loss of tolerance appears to be
mediated by both T cells and B cells. Many organs including
the kidney can be affected [9]. Direct action of autoantibodies,
deposition of immune complexes and pro-inflammatory
cytokines, particularly interferon (IFN) γ, have all been impli-
cated in disease pathophysiology [10-13].
There are at least four mouse models of lupus nephritis [14].
Both NZB × NZW F1 [15] and MRL/lpr mouse [16,17] strains
spontaneously develop autoimmune lupus nephritis. Female
mice from the NZB × NZW F1 cross (NZB/W) develop pro-
teinuria and only a small number (< 20%) survive to 52 weeks.
In MLR/lpr mice, the disease develops in both males and
females and is associated with the fas lpr mutation on the MLR
background. Mice develop significant proteinuria at 16 weeks
and show significant mortality rates (about 50%) by 20 weeks
[18,19]. Despite their independent derivation, lupus nephritis
in both MLR/lpr and NZB/W mouse models shows a remark-
ably efficacious response to sirolimus treatment [20-22].
Sirolimus (rapamycin) is an immunosuppressive drug that
binds to mTOR (mammalian target of rapamycin), a serine/
threonine kinase that regulates cellular proliferation and
metabolism and blocks G1 to S phase cell cycle progression,
interfering with T and B cell activation [23-25]. Sirolimus is
approved for the prevention of transplant rejection [26]. We
used our own data (presented here) and previously published
data on the efficacy of mTOR inhibitors in two mouse models
of lupus nephritis to infer that perturbations of the mTOR path-
way are critical to the development of lupus nephritis in both
these models. In order to assess the likelihood of mTOR path-
way involvement in human lupus, we examined the concord-
ance between the mTOR pathway interactome and genes




NZB/W (NZB × NZW F1 cross) females were purchased
from the Jackson Laboratory (Bar Harbor, ME). These mice
were maintained and studied under pathogen free conditions
in accordance with guidelines from the American Association
for the Accreditation of Laboratory Animal Care and the Insti-
tutional Animal Care and Use Committee of Wyeth Research.
Experimental design
Beginning at 20 weeks of age, disease progression was mon-
itored weekly by assessing proteinuria. A cohort of mice,
selected at 20 weeks of age, served as the 'asymptomatic'
group (n = 4). Once fixed proteinuria of 30 to 100 mg/dL had
appeared on two consecutive occasions, (generally at 25 to
29 weeks of age), the diseased mice were randomly assigned
to either the sirolimus-treated group (n = 6 mice) or the
untreated (disease) group (n = 6). Sirolimus, dissolved in car-
boxymethylcellulose (vehicle), was subcutaneously adminis-
tered three times weekly in single doses of 1 mg/kg or 5 mg/
kg for eight weeks. Mice were monitored weekly until 52
weeks of age.
Assessment of proteinuria
Urine was manually expressed from each mouse on a weekly
basis, collected into a sterile container and assayed for the
presence of protein (specifically albumin) using a colorimetric
method (Albustix Reagent Strips, Bayer Corporation, Elkhart,
IN).
Proteinuria evaluations were scored as follows: grade 0.5 =
'trace' proteinuria; grade 1 = about 30 mg/dL; grade 2 =
about 100 mg/dL; grade 3 = about 300 mg/dL; and grade 4
= more than 2000 mg/dL. If mice achieved a grade 4 reading
on two consecutive days they were euthanised.
Assessment of renal pathology
Kidneys were harvested from mice one to four months after an
eight-week course of treatment. Three to five mice were exam-
ined in each group. One-half of a kidney was fixed by overnight
immersion in 10% formaldehyde and paraffin-embedded. The
other half was snap frozen for RNA preparation. To determine
the extent of renal damage, sections were stained with H & E
and periodic acid-Schiff (PAS) and scored for pathological
changes. In addition, glomerulopathy was scored on a 0 to 5
scale. Severity grades were as follows: 0 = normal or within
normal limits; 1 = minimal or slight; 2 = mild; 3 = moderate; 4
= marked; 5 = severe.
RNA purification and microarray hybridisation
Snap frozen murine kidney tissue was homogenised in RLT
buffer containing 1% beta-mercaptoethanol using the polytron
and RNA purified by Qiagen RNeasy columns (Qiagen, Valen-
cia, CA). Eluted RNA was quantified using a Spectramax 96-
well plate UV reader (Molecular Devices, Sunnyvale, CA, USA)
monitoring A260/280 OD values. The quality of each RNA
sample was assessed by capillary electrophoresis alongside
an RNA molecular weight ladder on the Agilent 2100 bioana-
lyser (Agilent Technologies, Palo Alto, CA, USA).Available online http://arthritis-research.com/content/10/6/R127
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Microarray processing
Five micrograms of total kidney RNA was prepared from indi-
vidual NZB/W F1 mice of the following groups; untreated
mice at 12 weeks (n = 4); untreated F1 mice at 36 and 42
weeks combined (n = 6); and sirolimus-treated mice at 36 and
42 weeks combined (n = 6). The animals selected for expres-
sion analysis reported here were representative of multiple
studies performed that confirmed the data on proteinuria, mor-
tality rates and histopathology here.
Biotin-labelled cRNA was prepared using an oligo T7-primed
reverse transcription reaction followed by in vitro transcription
reaction with biotin-labelled UTP and CTP. cRNA 15 μg was
fragmented and hybridised to Mu11KsubA and Mu11KsubB
arrays (Affymetrix, Santa Clara, CA). Hybridised arrays were
washed and stained with Streptavidin R-phycoerythrin (Molec-
ular Probes Inc., Eugene, OR) using the GeneChip Fluidics
Station 400 (Affymetrix, Santa Clara, CA) and scanned with a
Hewlett Packard GeneArray Scanner (Hewlett Packard Com-
pany, Palo Alto, CA) according to the manufacturer's proto-
cols. All array images were visually inspected for defects and
quality. Arrays with excessive background, low signal intensity
or major defects within the array were eliminated from further
analysis. GeneChip MAS 5.0 software was used to evaluate
the hybridisation intensity, compute the signal value for each
probe set and make an absent/present call. GeneChip signal
data for the samples analysed in this study are available under
Accession Number [GEO:GSE12924] [27].
Data normalisation and filtering
GeneChips were required to pass standardised quality control
criteria. RNA quality was monitored by the ratio of frequencies
measured by independent probe sets representing 5' and 3'
regions of glyceraldehyde 3-phosphate dehydrogenase. This
ratio must be more than 0.4. Filtering criteria for individual
probe sets required that a probe set was called 'present' or a
signal of 50 or more in at least one of the samples. All filtering
criteria were passed by 6384 probe sets and were subject to
the statistical analysis described below, and probe sets that
did not meet these criteria were not included in subsequent
analyses.
Hierarchical clustering
For hierarchical clustering of probe sets and arrays, the Log-2
scale MAS5 expression values from each probe set were first
z-normalised so each probe set had a mean expression level
of zero and a standard deviation (SD) of one across all sam-
ples. Then these normalised profiles were clustered hierarchi-
cally using an unweighted paired group method with
arithmetic mean, and the Euclidean distance measure.
Identification of genes associated with lupus nephritis 
and response to sirolimus therapy
The disease-related fold change differences were calculated
by determining the difference in the log-2 signal of the 12-
week-old asymptomatic mice and the combined 36 and 42-
week-old diseased mice. Analysis of variance (ANOVA) was
performed using this metric to identify disease-related differ-
ences. Raw p values were adjusted for multiplicity of testing
using the false discovery rate (FDR) procedure of Reiner and
colleagues [28] using Spotfire (Somerville, MA). Genes with a
FDR p < 0.05 and an absolute fold change of two of more in
the comparison between disease and asymptomatic groups
were identified as being significantly associated with lupus
nephritis. Lupus nephritis genes were identified as being sig-
nificantly associated with response to sirolimus treatment if
they met an FDR p < 0.05, in comparison between sirolimus-
treated and disease groups. Those that failed to meet the FDR
p < 0.05 in the comparison of the sirolimus-treated group to
the disease group, did have a significant difference (FDR p <
0.05) in the comparison between sirolimus-treated and
asymptomatic groups, confirming a resistance to sirolimus
therapy.
Pathway analysis
Pathway analysis was performed using Ingenuity Pathways
Analysis (IPA) (Ingenuity Systems, Redwood City, CA), Meta-
Core (GeneGo Inc., St. Joseph, MI) and an in-house imple-
mentation of the sigPathway algorithm [29]. SigPathway is an
algorithm that identifies differentially expressed gene sets. An
FDR p < 0.01 was used to identify significantly changing gene
sets. Networks were built using genes that met FDR p < 0.05
within a gene set. Networks, canonical pathways and func-
tional processes for genes passing either the FDR p < 0.05
and an absolute fold change of two or more criteria and/or Sig-
Pathway filter FDR p < 0.05 were analysed using IPA. Human,
mouse and rat lupus-associated genes were identified using
the search tools within IPA and MetaCore. Rapalog-mTOR
pathway and its connectivity to the lupus nephritis disease
data and the lupus disease genes were explored using the
pathway building tools in IPA. The rapalog-mTOR pathway
interactome was built using IPA and all proteins were exported
to MetaCore to explore the human disease representation on
the mTOR pathway interactome. In MetaCore, a gene is con-
sidered to be associated with a condition (disease, pathologi-
cal or toxic process) as a biomarker if this gene or its product
(RNA or protein) has different properties in the disease and
healthy states. Such properties may include DNA characteris-
tics (eg, mutation, single nucleotide polymorphisms, chromo-
somal rearrangement); epigenetics (eg, methylation of a
promoter region, histone acethylation, nucleosome misplace-
ment); RNA level (eg, disease specific splice variant, higher/
lower expression level); or protein level (eg, disease-specific
isoform, mutant isoform, subcellular localisation, post-transla-
tional modification, abundance). These genes are used to gen-
erate human 'disease biomarkers' networks using direct
interactions between biomarker genes and proteins from their
MetaBase database. I2E (from Linguamatics Ltd., Cambridge,
UK) and clinical database findings were used to validate someArthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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of the relationships between sirolimus analogues and various
human diseases identified in the mTOR pathway interactome.
Results
Short course therapy with sirolimus prevents onset of 
murine lupus and renal damage
Treatment with sirolimus maintained 100% survival at age one
year, although survival in the control mice was only 20% (Fig-
ure 1a). Similarly, mice treated with sirolimus had minimal or no
increase in proteinuria and were asymptomatic for more than
three months after cessation of treatment (Figure 1b). Collec-
tively, these findings demonstrated the sustained benefit of a
short course of sirolimus therapy initiated early in disease.
To verify the therapeutic effects of sirolimus therapy on renal
pathology, kidney tissues were evaluated microscopically for
renal lesions and cellular infiltrates that were anticipated to
develop in NZB/W F1 mice at 36 weeks. Light microscopy of
kidney sections from vehicle-treated nephritic mice revealed
glomerulonephritis and interstitial inflammation, and also pro-
teinaceous tubular casts, consistent with their proteinuria (Fig-
ure 2b). Kidney sections from 12-week-old mice before
disease onset (Figure 2a) and from 36-week-old sirolimus-
treated mice (Figure 2c) revealed minimal renal pathology.
There was almost a complete absence of glomerular prolifera-
tion, interstitial infiltrates and casts. Histology scores for renal
inflammation, lymphocytic infiltrates and tubular atrophy are
shown in Table 1. There was good correlation between the
level of proteinuria and the severity of pathophysiological
changes observed in the kidneys. We have also collected
extensive data in this model showing a dramatic decrease in
anti-dsDNA titre with sirolimus treatment (see additional file 1).
Collectively, these findings confirmed the previously reported
beneficial effects of sirolimus treatment on the onset and
pathology of lupus nephritis in this mouse model [20,22,30].
Identification of the disease-associated transcriptome
RNA was prepared from tissue corresponding to one-half of a
kidney containing all cortex and medullary structures and har-
vested from asymptomatic mice at 12 weeks, diseased mice
at 36 and 42 weeks and sirolimus-treated mice at the same
age. Expression levels were assessed using Affymetrix Gene-
Chips (Affymetrix, Santa Clara, CA). There were 6384 probe
sets that met the criteria for inclusion in analysis. The expres-
sion patterns of these 6384 probe sets across groups were
visualised using an unsupervised clustering algorithm, which
assigns samples to clusters (nodes) based on similarity of
transcriptional pattern. A visual representation of differential
gene expression is shown in additional file 2. Samples were
grouped into three nodes: asymptomatic 12-week-old group;
36 and 42 week diseased group; and 36 and 42 week
sirolimus-treated group. This segregation indicated that the
renal RNA expression patterns of these three groups were dis-
tinct from each other. We then identified 1141 probe sets that
differed between the asymptomatic and 42-week diseased
groups with FDR p < 0.05 and an average fold change more
than 1.5. As seen in Figure 3, these 1141 probe sets showed
an almost identical change relative to the asymptomatic group
in the comparison with the 36-week diseased group (Pearson
correlation = 0.97).
Based on the similarities in the 36-week and 42-week mice,
ANOVA with FDR adjustment was performed comparing the
expression values of the disease group (consisting of
untreated 36- and 42-week-old mice) to those of the asympto-
matic 12-week-old group. This analysis yielded 195 differen-
tially expressed immunoglobulin probe sets and 547
differentially expressed non-immunoglobulin probe sets (using
significance criteria of FDR p ≤ 0.05 and a fold change differ-
ential ≥ 2). The disease-associated expression pattern of the
547 non-immunoglobulin transcripts included both up-regu-
lated and down-regulated non-immunoglobulin genes (Figure
4a). All 195 immunoglobulin probe sets were elevated in dis-
ease compared with asymptomatic animals (Figure 4b). Of
these 547 probe sets, protein interaction data from the litera-
ture is available in IPA for 387 genes. We have used this set
of 387 genes for pathway analyses as described below. The
complete list of non-immunoglobulin genes with functional
Figure 1
Proteinuria and survival measurements Proteinuria and survival measurements. (a) Survival and (b) pro-
teinuria were measured weekly starting at 29 weeks of age (n = 10). 
Grade 0.5 proteinuria = 'trace'; grade 1 = about 30 mg/dL; grade 2 = 
about 100 mg/dL; grade 3 = about 300 mg/dL, a clinically significant 
level; grade 4 = more than 2000 mg/dL; grade 5 = death.Available online http://arthritis-research.com/content/10/6/R127
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annotation is included in Additional file 3. An analysis of the
expression of these genes in kidneys of young (12 weeks old)
versus aged (32 weeks old) C57Bl/6 mice by ANOVA with
FDR adjustment showed no significant age-related changes in
the 547 transcripts associated with lupus nephritis.
Identification of nephritis-associated probe sets 
modulated by sirolimus treatment
Of the 547 non-immunoglobulin probe sets associated with
nephritis at 36 and 42 weeks, 365 were modulated toward
asymptomatic levels by sirolimus treatment (with 150 that
were not modulated). Those that failed to meet the FDR p <
0.05 in the comparison of the sirolimus-treated group to the
disease group, did have a significant difference (FDR p <
0.05) in the comparison between sirolimus treated and asymp-
Table 1
Histopathology evaluation of kidneys from NZB/W F1 hybrid female mice at 42 weeks of age
Group Animal Interstitial inflammation Glomerular nephritis Tubular dilation
Therapy Cellularity Membrane thickness
None 1 +2 -2 +2 +3
None 2 +3 -1 +3 +3
None 3 +2 -1 +3 +2
None 4 +3 -3 +3 +4
None 5 +3 -3 +3 +4
None Mean +2.6 -2 +2.8 +3.2
Sirolimus* 1 (+1) 0 +1 +1
Sirolimus 2 (+1) 0 +1 0
Sirolimus 3 (+2) 0 0 0
Sirolimus 4 0 0 0 0
Sirolimus 5 (+1) 0 0 0
Sirolimus Mean +1 0 +0.4 0
p value, untreated versus treated 0.004 0.002 0.00006 0.0001
0 = normal, 1 = slight, 2 = mild, 3 = moderate, 4 = marked, 5 = severe.
* denotes focal not diffuse.
Figure 2
Kidney histology. Representative sections of renal cortex from NZB × NZW F1 female mice Kidney histology. Representative sections of renal cortex from NZB × NZW F1 female mice. (a) Section of kidney with glomeruli (arrows) and 
tubules that are within normal limits from a 12-week-old mouse. (b) Section from an untreated 36-week-old mouse. Glomeruli (arrows) are small with 
markedly thickened basement membranes and decreased numbers of cells (glomerulosclerosis). Tubules are dilated and contain protein casts or 
droplets in the lumens. (c) Section from a 36-week-old mouse treated with sirolimus has kidneys that are within normal limits. Glomerular (arrows) 
basement membranes are slightly thicker than those in the untreated 12-week-old mice. H & E, 40× original magnification.Arthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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tomatic groups, confirming a resistance to sirolimus therapy.
The comparative expression levels for the 365 sirolimus-mod-
ulated probe sets are shown in Figure 5. Both up- and down-
regulated genes are among those modulated by treatment.
The changes associated with therapy and amelioration of dis-
ease can be found in Additional file 3.
Biological annotation of disease and drug-responsive 
genes
Transcriptional analysis of kidney tissue in this model of nephri-
tis generated three gene signatures for biological pathway
comparison: disease-associated genes (identified by compar-
ison of disease versus asymptomatic cohorts), sirolimus-
responsive disease-associated genes (identified by compari-
son of diseased (control) versus sirolimus-treated cohorts),
and sirolimus non-responsive disease associated genes (iden-
tified by comparison sirolimus-treated cohorts versus
asymptomatic). Using the SigPathway algorithm, apoptotic
gene sets and several mitochondrial gene sets (mitochondrial
inner membrane and inner membrane proteins) were identified
as being significantly associated with disease. Mitochondrial
regulation of apoptosis was evident from these various gene
sets, and this process is depicted in Figure 6. Sirolimus treat-
ment restores the expression level of these gene sets to the
asymptomatic levels, rendering this pathway insignificant (by
SigPathway in the comparison of the sirolimus-treated and
asymptomatic groups). Using a combination of SigPathway
and/or IPA, other immuno-inflammatory networks linked to dis-
ease were identified. These included the antigen presentation
pathway (Figures 7 and 8), complement pathway (Figures 9
Figure 3
Close similarities in disease-related gene expression changes in kid- neys at 36 and 42 weeks of age Close similarities in disease-related gene expression changes in 
kidneys at 36 and 42 weeks of age. Between the 42-week diseased 
group and the asymptomatic group with false discovery rate (FDR) p < 
0.05 and average fold change more than 1.5, 1141 probe sets were 
identified to be differentially expressed. Average fold changes of these 
1141 probe sets for the 42-week comparison with the asymptomatic 
group are shown on the X axis. The average fold changes for the 36-
week comparison with the asymptomatic group are on the Y axis. Note, 
that although the magnitude of the changes at 42 weeks tended to be 
slightly larger than those at 36 weeks, the direction of change of all 
1141 probe sets was the same and the magnitude of the changes are 
very well correlated (Pearson correlation = 0.97). The criteria used to 
identify 1141 probe sets are more relaxed than those used to identify 
lupus nephritis genes. This was to show that even the smaller changes 
(1.5 versus twofold change) observed in this model are well correlated 
at 36 weeks and 42 weeks.
Figure 4
Expression changes in transcripts associated with disease progression Expression changes in transcripts associated with disease pro-
gression. Scatter plot showing the expression levels of dysregulated 
probe sets expressed in (NZBxNZW)F1 kidneys of mice with lupus 
nephritis (older mice) (Y axis) compared with expression levels in 
asymptomatic (younger) mice (X axis). (a) Expression levels of 547 non-
immunoglobulin (Ig) probe sets significantly associated with disease, 
46% of which are expressed at higher levels in diseased kidney. (b) 
Expression levels of 195 immunoglobulin probes sets, 100% of which 
are expressed at higher levels in diseased kidney.
Figure 5
Maintenance of normal levels of nephritis-associated gene expression  with sirolimus treatment Maintenance of normal levels of nephritis-associated gene expres-
sion with sirolimus treatment. Of the 547 probe sets expressed at 
significantly different levels in diseased and asymptomatic kidney, 365 
were not significantly different (false discovery rate (FDR) > 0.05) 
between asymptomatic and sirolimus-treated kidney. Probe sets are 
shown ordered by expression level in asymptomatic kidney.Available online http://arthritis-research.com/content/10/6/R127
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and 10), and IL1 and IL10 signalling pathways (data not
shown). Close examination of the antigen presentation path-
way in the disease tissue identified elevated transcriptional
expression of multiple components of the H2 locus involved in
antigen presentation to both CD8+ and CD4+ T cells (Figure
7). A similar pattern is seen for these transcripts in the compar-
ison of the disease and treated groups. The data show a treat-
ment-dependent return to asymptomatic levels for some
genes of this pathway, and a treatment dependent decrease
below asymptomatic levels for some other genes (Figure 8).
Evaluation of the complement pathway in the disease tissue
shows increased transcriptional expression of key compo-
nents of the classical pathway, C1qa, C1qb, C1qc, C4 and
C3, the latter two are also components of the alternate path-
way (Figure 9). Using SigPathway, additional members of the
complement pathway C8, CFH and CFD were identified.
Treatment with sirolimus returned the expression of the C3
and C1q to asymptomatic levels, while C4 in the classical
pathway remained elevated (Figure 10 and data not shown).
A critical signalling pathway involved in mediating an inflamma-
tory response is the JAK-STAT and MAP kinase pathway.
Figure 6
Mitochondrial regulation of the apoptotic pathway is altered in disease and modulated by sirolimus treatment Mitochondrial regulation of the apoptotic pathway is altered in disease and modulated by sirolimus treatment. Expression of mitochondrial 
and cytosolic components involved in apoptosis in nephritis compared with asymptomatic tissue. The thick grey oval represents the mitochondria. 
The horizontal double line represents the plasma membrane. Two genes (DDX20 and MLH1) known to be involved in apoptosis were not connected 
to the main pathway in IPA. Green colour indicates higher level of expression in disease and red colour indicates lower level of expression in disease. 
The names of the genes are in "nodes". The shape of the nodes is related to gene function/family membership. The lines between the nodes repre-
sent the connectivity between genes. Solid lines indicate direct protein-protein interactions. Dotted lines represent indirect interactions.Arthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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Increased levels of transcripts for pathway members including
JAK3, STAT3, SOCS3, PTPN1, CDKN1A, RRAS and MAPK1
were observed in nephritis. After treatment with sirolimus
these pathways exhibit transcriptional expression levels similar
to asymptomatic levels.
Rapalog-mTOR canonical pathway and links to mouse 
lupus nephritis genes
Networks were built in an effort to understand the broad rang-
ing beneficial effects of the mTOR pathway inhibitor, sirolimus,
in NZB/W lupus nephritis. The first step in this process was to
build a rapalog-mTOR pathway. This pathway consisted of the
mTORC1 complex (mTOR, GBL, Raptor), the mTORC2 com-
plex (mTOR, GBL, AVO3), the immediate downstream targets
of mTOR – RPS6KB1 and RPS6KB2, and the upstream effec-
tors of mTOR – AKT1, AKT2, TSC1, TSC2. In addition, rapal-
ogs, such as sirolimus, temsirolimus and everolimus as well as
all members of the immunophilin protein family that bind to the
immunosuppressants FK506 and rapamycin, were included in
the rapalog-mTOR pathway. Downstream connectivity of the
rapalog-mTOR pathway to the 387 lupus nephritis genes was
explored using the IPA. Of the 387 genes, 32 can be placed
immediately downstream of the rapalog-mTOR pathway. An
additional 25 of these are connected to the pathway through
various types of functional protein interactions (eg, phosphor-
ylation, binding etc).
Therefore, based on curated protein-protein and drug-protein
interactions in the literature we determined that about 15% of
the identified 387 nephritis genes interact with components of
the rapalog-mTOR pathway. We therefore posed the ques-
tion: Of the genes linked to lupus in the published literature,
how many can be placed in the rapalog-mTOR pathway?
Using curated findings in IPA, at least 50% of the known
lupus-associated genes in IPA and Metacore interact with
components of the rapalog-mTOR pathway. The large num-
bers of connections between the lupus nephritis genes we
identified, the rapalog-mTOR pathway, and previously identi-
Figure 7
Antigen presentation pathway altered in disease Antigen presentation pathway altered in disease. Expression of components of the antigen presentation pathway in nephritis compared with 
asymptomatic tissue. Green colour indicates higher level of expression in disease. The names of the genes are in "nodes". The shape of the nodes is 
related to gene function/family membership. The lines between the nodes represent the connectivity between genes. Solid lines indicate direct pro-
tein-protein interactions. Dotted lines represent indirect interactions.Available online http://arthritis-research.com/content/10/6/R127
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fied genes associated with lupus are shown schematically in
Figure 11. The individual genes in each of these categories are
listed in Additional file 4.
Building the mTOR pathway interactome
All proteins known to interact with members of the rapalog-
mTOR pathway, upstream and downstream were used to cre-
ate the mTOR pathway interactome, consisting of 570 pro-
teins (see Additional file 5). The magnitude of this 570 protein
interactome is likely to be due in part to some high connectivity
proteins such as the AKT gene group, which regulate many
pathways. The 570 proteins from this interactome were
imported into Metacore to query human diseases significantly
associated with the mTOR pathway interactome. Significantly
associated human diseases likely to be perturbed by mTOR
pathway dysfunction were identified using the functional
enrichment category within Metacore that relies on curated
human disease specific networks.
Human lupus and genes of the mTOR pathway 
interactome
Various cancer and non-cancer human diseases were identi-
fied as being significantly associated with the mTOR pathway
interactome. A few cancers, such as ovarian neoplasm and
pancreatic neoplasm, topped the list of associated diseases,
and remarkably these were followed by lupus with significance
of association p value of about E-8.5. Other non-cancer dis-
eases that showed a less significant association are diabetes,
obesity, Alzheimer's disease, multiple sclerosis and arthritis, all
having an association of p < 0.01. Notably, the p values for the
other pro-inflammation diseases were much less significant
than those for lupus. For example, p values for both multiple
sclerosis and arthritis are about 1E-3.
The genes in the mTOR pathway interactome that are associ-
ated with lupus are, in large part, distinct from the genes
involved in the other non-cancer diseases. This is evident from
Figure 8
Antigen presentation pathway modulated by sirolimus treatment Antigen presentation pathway modulated by sirolimus treatment. Expression of components of the antigen presentation pathway in sirolimus-
treated tissue compared with asymptomatic tissue. Green colour indicates higher level of expression in sirolimus-treated tissue and red colour indi-
cates lower level of expression in sirolimus-treated tissue. Grey colour indicates no significant difference in expression level. The names of the genes 
are in "nodes". The shape of the nodes is related to gene function/family membership. The lines between the nodes represent the connectivity 
between genes. Solid lines indicate direct protein-protein interactions. Dotted lines represent indirect interactions.Arthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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the top scoring Gene Ontology cellular processes for each of
these diseases. For example, in Metacore, the top scoring
Gene Ontology cellular processes for lupus are related to
apoptosis and cell death, while those for diabetes are related
to carbohydrate metabolism, and those for obesity are related
to fat metabolism. Both diabetes and obesity show a much
more significant association with the mTOR interactome than
any pro-inflammatory disease other than lupus.
Discussion
NZB/W mice develop nephritis closely resembling that seen in
human patients with lupus nephritis. Here we show that an
eight-week course of 5 mg/kg sirolimus delivered three times
a week starting at disease onset (about 25 weeks) and contin-
uing for eight weeks markedly reduced symptoms of disease
as measured by proteinuria, kidney histopathology and sur-
vival. By 52 weeks of age all treated mice were alive despite
cessation of treatment many weeks earlier. Both results
Figure 9
Complement pathway altered in disease Complement pathway altered in disease. Expression of components of the complement pathway in nephritis compared with asymptomatic tissue. 
Green colour indicated increased expression and red colour indicates a decreased expression in nephritis tissue. Grey colour indicates that the fold 
change and FDR p < 0.05 or the sigPathway FDR p < 0.05 filters were not met. The names of the genes are in "nodes". The shape of the nodes is 
related to gene function/family membership. The lines between the nodes represent the connectivity between genes. Solid lines indicate direct pro-
tein-protein interactions. Dotted lines represent indirect interactions.Available online http://arthritis-research.com/content/10/6/R127
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Figure 10
Complement pathway modulated by sirolimus treatment Complement pathway modulated by sirolimus treatment. Expression of components of the complement pathway in sirolimus-treated tissue com-
pared with asymptomatic tissue. Green colour indicates increased expression and red colour indicates decreased expression. Grey colour indicates 
that the fold change and FDR p < 0.05 or the sigPathway FDR p < 0.05 filters were not met. The names of the genes are in "nodes". The shape of 
the nodes is related to gene function/family membership. The lines between the nodes represent the connectivity between genes. Solid lines indi-
cate direct protein-protein interactions. Dotted lines represent indirect interactions.Arthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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described here and previously reported studies [20,22,30],
establish that sirolimus treatment prevents progression of
autoimmune nephritis and prolongs survival in NZB/W mice. A
comparable effect of sirolimus treatment has been observed in
MRL/lpr mice, a second model of lupus and lupus nephritis
[21].
We identified genes expressed at abnormal levels in NZB/W
kidneys by comparing RNA levels in asymptomatic young mice
and older mice with symptoms of lupus nephritis. These lupus
nephritis genes were further shown to not be associated with
the normal ageing process based on the observed differences
between healthy young and old C57BL6 mice. A broad range
of biological functions was represented among the lupus
nephritis genes identified in this study. As expected, given the
loss of kidney function, the vast majority of genes involved in
metabolic pathways are down-regulated in nephritis and, given
the inflammatory nature of the disease, many of the signalling
pathway genes are up-regulated. Glomerular disease is a sig-
nificant component in lupus nephritis. A recent study identified
a glomerulus-enriched gene set [31]. We used data from this
study to determine if the nephritis-associated genes are
enriched in the glomerular gene set. We found a highly signif-
icant over-representation of the glomerular genes (chi-square
value of 49.29 with one degree of freedom) consistent with
glomerular involvement.
A recent study by Liu and colleagues reported on 126 nephri-
tis-associated genes in the MRL/lpr model [17]. Of these, 37
genes were present in the nephritis-signature reported here.
Commonalities were noted in the nephritis signatures (and this
includes the directionality of change in the disease state)
between these two models, such as the antigen presentation
and complement pathways as well as various IFN-regulated
genes and immunoglobulins. A good overlap (21 genes) was
also noted between our mouse nephritis gene set and 68
human lupus nephritis genes derived from laser-captured
glomeruli from SLE patients [32]. Additional similarities may be
present, but probably lie outside the statistical parameters of
both datasets.
A profound 'normalisation' of expression levels of lupus nephri-
tis genes was observed in mice treated with sirolimus, both for
metabolic as well as signalling pathways. Affected metabolic
pathways in lupus nephritis include fatty acid degradation, gly-
colysis pathways and leucine/valine/isoleucine degradation.
Figure 11
Shortest path from the mTOR pathway to lupus nephritis genes and lupus genes Shortest path from the mTOR pathway to lupus nephritis genes and lupus genes. The information shown schematically in this figure can be 
viewed in table form in Additional file 4. Solid lines indicate direct interactions and dotted lines indicate indirect interactions. mTOR pathway is indi-
cated in the red box, the lupus nephritis genes in the yellow box and the lupus genes in the green box. The green colour nodes indicate genes 
expressed at higher levels in disease and red indicates lower levels in disease. Grey colour indicates that the fold change and FDR p < 0.05 filters 
were not met. The names of the genes are in "nodes". The shape of the nodes is related to gene function/family membership. The lines between the 
nodes represent the connectivity between genes. Solid lines indicate direct protein-protein interactions. Dotted lines represent indirect interactions.Available online http://arthritis-research.com/content/10/6/R127
Page 13 of 16
(page number not for citation purposes)
Transcripts for BCKDHA and DBT, two enzymes in the
branched chain amino acid metabolism pathway required for
the catabolism of leucine, valine and isoleucine, are reduced in
nephritis, perhaps leading to the accumulation of leucine in
diseased tissue. Interestingly, leucine activates the target of
sirolimus inhibition, mTOR, leading to increased protein syn-
thesis [33], and in addition we noted an increase in ribosomal
RNA transcripts in the disease state. This physiological con-
nection suggests that mTOR pathway activation may be
increased by leucine in disease, providing perhaps an addi-
tional mechanism for sirolimus efficacy. Levels of these tran-
scripts were returned to asymptomatic levels in sirolimus-
treated mice. Several genes in the mitochondrial electron
transport chain are also down-regulated in the disease state,
and mitochondrial dysfunction has been implicated in kidney
function impairment [34].
Reflecting the pro-inflammatory functions of nephritis, genes
such as JAK3, STAT3 and MAPK1 involved in signalling path-
ways (JAK/STAT, MAP kinase, antigen presentation, IL1/IL10)
are expressed at higher levels in the disease state. Also
SOCS3, a negative regulator of JAKs and PTPN1 and
CDKN1A, a negative regulator of STATs, are also elevated in
the disease state. Although activation of these signalling path-
ways occurs through phosphorylation-dephosphorylation
events of pathway components, it can be noted here that this
pathway is also dysregulated at the transcriptional level in
lupus nephritis. This complex dysregulation of the JAK/STAT
pathway, which drives production of multiple cytokines and
other inflammatory mediators, is returned to asymptomatic lev-
els on sirolimus treatment. PTPN1, a negative regulator of
STATs, is a notable exception, suggesting a link between the
quiescence of this pathway with amelioration of disease. Con-
sistent with the activation of this signalling pathway, genes
involved in immune system cascades, such the IFN-regulated
genes (IRF1, IRF7, OAS1, IFITM3, IFI27 and IGTP), and sig-
nalling by IL2 subfamily of type 1 cytokines (IL2Rγ) were also
up-regulated in the disease state and are down-regulated by
sirolimus.
Genes of the complement pathway known to be involved in
renal damage, such as C3, C4, C1QA, CCL13 and FCGR2a,
are also expressed at higher levels than in the untreated group.
C3, C4 and C1QA play a role in antigen clearance. Using sig-
Pathway [29], an algorithm that identifies differentially
expressed gene sets, additional components of the
complement pathway are transcriptionally elevated in the dis-
eased renal tissue. Our results suggest that the complement
components in the early parts of both the classical and alter-
nate pathways are elevated in nephritis, while one component
of the membrane attack complex, further downstream in the
complement pathway, is down-regulated. C1q and C3, but not
C4, were normalised by treatment. Complement pathway
components are known to be significant contributors to renal
damage. C3 deposition in the kidney has been observed in
both human lupus nephritis and in murine models [35]. The
elevated levels of C4 during disease amelioration is consistent
with the concept that the early members of the classical path-
way may be important in reducing disease pathology by clear-
ing immune complexes and apoptotic cells [35,36]. Our
profiling analysis also identified a large number of immu-
noglobulin transcripts elevated in the kidney tissue consistent
with the role of autoantibodies and immune complex deposi-
tion in pathology.
To understand the mechanism by which sirolimus normalised
such a wide range of biological processes, networks were
built around the nephritis genes and the rapalog-mTOR path-
way. Using curated findings from the literature, the shortest
path for about one sixth of the 387 nephritis genes was
defined to be either 0 or one-step downstream of the rapalog-
mTOR pathway. This suggests a close functional association
of mTOR pathway with disease mechanisms. In the context of
the findings reported here, it is worth noting that steroid and
cyclophosphamide, known to ameliorate lupus, directly impact
some components of the mTOR pathway (data not shown).
In additional to preventing nephritis, sirolimus also had striking
effects on the anti-DNA antibody titres in mice with lupus [20-
22,30], so we addressed the connectivity of genes linked to
any form of lupus with the mTOR pathway. About 50% of the
lupus genes curated as lupus disease genes from human and
rodent species in Ingenuity and MetaCore can be linked to the
rapalog-mTOR pathway. The connectivity would, no doubt
have been higher with the use of automatically extracted rela-
tionships from the biomedical literature. However, the algo-
rithms used in automatic extractions cannot approximate
human reasoning and return a mixture of true and false posi-
tives. Therefore, we relied exclusively on manually curated
databases of protein findings and our results should be viewed
as a lower estimate of connectivity.
To assess the significance of the association between human
lupus genes and the mTOR pathway, we built an mTOR path-
way interactome (ie, a network consisting of proteins that inter-
act with the mTOR pathway) using IPA. We then queried
which human disease networks (manually curated) in Meta-
core were best represented in the mTOR pathway interac-
tome. Of the 87 human disease networks represented in
Metacore, human lupus was identified as being highly signifi-
cant, with only two cancers showing more significant associa-
tions. Additional cancer and non-cancer diseases were also
identified through this process, including Alzheimer's disease
and other autoimmune diseases such as multiple sclerosis and
arthritis. Indeed recent work has uncovered a strong link
between the mTOR pathway, Treg function and autoimmunity.
Rapamycin was shown to inhibit AKT-mediated repression of
FOXP3 (and AKT is upstream of mTOR). FOXP3 is a critical
player in Treg cell differentiation and maintenance and defi-
ciency of FOXP3 in both humans and mice is associated withArthritis Research & Therapy    Vol 10 No 6    Reddy et al.
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multi-organ autoimmunity and lymphoproliferative disorders
[37-40].
Having investigated the human disease-mTOR pathway con-
nectivity, we then widened our analysis by exploring the validity
of the claim of connectivity by searching the literature for data
showing the effects on rapalogs on these human diseases. By
conducting these analyses independently of Metacore, we
confirmed the relationship between the mTOR pathway and
some human diseases, such as multiple sclerosis [41,42], dia-
betes [43-45], arthritis [46] and some cancers [47,48]. A
search of the clinical trial database [49] reports ongoing clini-
cal studies with rapalogs in a number of these diseases, and
the analyses we present here support such studies. Indeed
early clinical results on the effects of sirolimus treatment of
lupus patients show promise. Nine SLE patients that had been
treated unsuccessfully with other immunosuppressive drugs
had significantly improved disease scores after sirolimus treat-
ment (BILAG p = 0.0218, SELDAI p = 0.00002) [50], and
another clinical study is in progress [51].
Our analyses indicate that the coverage of protein-protein
interactions in curated databases such as Ingenuity and Met-
aCore is comparable with up-to-date text-mined content
derived using MedScan, a data mining/natural language
processing tool (Ariadne Inc., Rockville, MD). For example,
Ingenuity has 80 and MetaCore has 65 proteins/complex/
groups that interact with the mTOR protein and MedScan
identifies 115 proteins that interact with the mTOR protein.
This level of overlap indicates a comprehensive coverage in
the databases used for these analyses.
Conclusion
Given our results and the results of others showing that inhibi-
tion of the mTOR pathway prevents progression of lupus
nephritis in various mice models, we reasoned that perturba-
tions of the mTOR pathway can lead to the phenotype of lupus
nephritis. We also assessed the involvement of the mTOR
pathway in human lupus by building the mTOR pathway inter-
actome (genes connected to the mTOR pathway) and using
bioinformatic algorithms to determine the significance of the
overlap between the mTOR interactome and the published
findings on genes involved in human lupus. We found a highly
significant overlap. We suggest a similar approach of assess-
ing significance of overlap between genes linked to human
diseases and networks controlling animal model perturbations
can be useful in understanding the relevance of animal models
and the exploration of new indications for established
therapies.
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